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quality of life, (2) disease flares, and (3) impact on cost. 
Eleven full-text publications were identified; only three 
were RCTs. Study results suggest that dosing down may be 
an option in many patients who have achieved remission or 
low disease activity. However, some patients are likely to 
experience a disease flare. Across the studies, the definition 
of disease flare and the down-titration criteria were incon-
sistent, making it difficult to conclude which patients may 
be appropriate and when to attempt down-titration. Studies 
have evaluated the practice of dosing down biologic therapy 
in patients with RA; however, a relatively small number of 
RCTs have been published. Although down-titration may be 
an option for some patients in LDA or remission, additional 
RCTs are needed to provide guidance on this practice.
Keywords Biological therapy · Rheumatoid arthritis · 
Dose–response relationship · Systematic review
Abstract Biologic therapies have improved the manage-
ment of rheumatoid arthritis (RA) and the treat-to-target 
approach has resulted in many patients achieving remis-
sion. In the current treatment landscape, clinicians have 
begun considering dose reduction/tapering for their patients. 
Rheumatology guidelines in Asia, Europe, and the United 
States include down-titration of biologics but admit that the 
level of evidence is moderate. We conducted a systematic 
literature review to assess the published studies that evaluate 
down-titration of biologics in RA. The published literature 
was searched for studies that down-titrated the following 
biologics: abatacept, adalimumab, certolizumab, etanercept, 
golimumab, infliximab, rituximab, and tocilizumab. Eligi-
ble studies included randomized controlled trials (RCTs), 
non-RCTs, observational, and pharmacoeconomic studies. 
The outcomes of interest were (1) efficacy and health-related 
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory rheu-
matic disease associated with substantial morbidity, dis-
ability, and impaired quality of life [1, 2]. The introduction 
of biologic therapies (referred to as biologics), including 
tumor necrosis factor (TNF) inhibitors, interleukin (IL)-1 
and IL-6 inhibitors, and B or T cell activation inhibitors, 
has had a significant impact on the treatment of RA. These 
agents have improved the control of disease activity, ena-
bling some patients to achieve disease remission. The cur-
rent treatment strategy is “treat-to-target,” with the goal of 
achieving low disease activity (LDA) or remission early in 
the disease course [3, 4]. It is recommended that patients 
continue therapy to remain in LDA or remission. There are 
a few situations in which treatment may be stopped or sus-
pended (drug holiday), such as surgery or pregnancy [5].
Since remission is an attainable goal, clinicians are now 
considering dose reduction, also referred to as dose taper-
ing or down-titration. Recognizing this trend, the 2015 
American College of Rheumatology (ACR) Guideline for 
the Treatment of Rheumatoid Arthritis [3] now includes 
downward tapering of disease-modifying antirheumatic 
drug (DMARD) therapy, anti-TNF therapy, non-TNF bio-
logics, or tofacitinib in patients with established RA who 
have achieved remission. What is not included is a stand-
ardized definition of remission, such as how long patients 
should be in remission prior to tapering down the dose. This 
recommendation is noted to be conditional, and the level of 
evidence for tapering is considered moderate to very low [3].
Guidelines from the European League Against Rheuma-
tism (EULAR) and the Asia Pacific League of Associations 
for Rheumatology (APLAR) also include statements that 
tapering of biologic therapy can be considered if a patient 
is in persistent or extended remission [6, 7]. The strength of 
these recommendations is considered moderate to high. The 
recommendations from these three guidelines are provided 
in Table 1.
Despite publication of these guidelines, information on 
which patients are appropriate for down-titration and the 
long-term consequences of such dosing (e.g., radiographic 
changes, subclinical inflammation or disease flares demon-
strated by a return of symptoms) is limited [8]. As a result, 
the evidence to support down-titration may be inadequate. 
We conducted a systematic literature review (SLR) to evalu-
ate the published data available on down-titration of bio-
logics, and to assess whether sufficient evidence exists to 
support this treatment practice. The objectives of the SLR 
were to (1) compare the effect of down-titration of biolog-
ics with standard dosing of biologics on clinical efficacy 
and health-related quality of life (HRQoL); (2) determine 
how investigators defined a disease flare in different studies; 
(3) assess how investigators decided that certain patients 
were appropriate for a decreased dose of the biologic and 
(4) evaluate the impact of decreasing the dose on the cost of 
biologic therapy.
Methods
Search strategy
An electronic literature search was conducted, utilizing the 
following databases: Medline, Embase, Cochrane Central 
Register of Controlled Trials, Cochrane Database of Sys-
tematic Review, National Health Services Economic Evalu-
ation Database, Health Technology Assessment Database, 
and Database of Abstracts of Reviews of Effects. Detailed 
search strategies are provided in Online Resource 1. Initially, 
we planned to evaluate both down-titration and up-titration 
of biologics in patients with RA, ankylosing spondylitis, and 
non-radiographic axial spondyloarthritis, and the literature 
search was designed in this manner. However, to provide a 
more focused review, this report only summarizes the litera-
ture on down-titration of biologics in patients with RA. The 
search was executed on February 2, 2015, and the results 
were limited to references published from January 2000 to 
February 2015 in the English language.
Study selection
Two levels of screening were employed. At the level 1 
screening, one reviewer screened the titles and abstracts of 
publications identified in the literature search for eligibil-
ity according to the criteria provided below. The full texts 
of abstracts and titles that passed level 1 screening were 
obtained for further review (level 2 screening). Any study 
ineligible for inclusion was excluded and the rationale for 
exclusion was documented. A second reviewer performed a 
quality check, and if the discrepancy level reached 5%, then 
the study selection was re-evaluated. Additionally, an inde-
pendent reviewer screened 20% of the publications excluded 
at this stage and reviewed all included publications. Any dis-
crepancies were resolved by a consensus among reviewers.
Eligibility criteria and data extraction
Randomized controlled trials (RCTs), non-randomized 
controlled trials (nRCTs), observational studies, and 
pharmacoeconomic studies that were available as full-
text publications were eligible for inclusion. RCTs were 
included regardless of blinding of the patients and inves-
tigators. Observational studies and nRCTs supplemented 
the clinical data from RCTs and captured long-term effi-
cacy data. Pharmacoeconomic studies provided economic 
and outcomes data related to dose-titration. Studies were 
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only considered if the patients were ≥18 years of age. 
The biologic therapies of interest included eight that were 
approved by regulatory authorities: abatacept (ABA), 
adalimumab (ADA), certolizumab pegol (CZP), etaner-
cept (ETN), golimumab (GOL), infliximab (INF), rituxi-
mab (RTX) and tocilizumab (TCZ). Review articles, case 
reports, letters, and editorials were excluded, but the ref-
erences were reviewed for relevant studies. Data from the 
included studies were collected on a customized grid to 
ensure that all relevant information was obtained (Online 
Resource 2).
Risk of bias assessment
The quality of RCTs was assessed using the recommenda-
tions from the National Institute for Health and Clinical 
Excellence single technology appraisal manufacturer’s 
template [9]. The quality of all nRCTs and observational 
studies was evaluated using the Downs and Black instru-
ment [10], and cost-effectiveness studies were evaluated 
using Drummond’s checklist for assessing economic eval-
uations [11].
Records identified through database searching
Full-text articles and conference abstracts for RA, AS and nr-axSpA 
Medline®: n=5,994
Embase®: n=14,492
Cochrane Library: n=1,099
Total: n=21,585
Level 1 Screening, after duplicates 
removed
Records: n=17,469
Records excluded: 
n=17,095
Level 2 Screening
Full-text articles and conference 
abstracts assessed for eligibility: 
n=374
Records excluded: n=287
- Not an intervention or population of interest:  
n=133
- Inadequate outcome measures: n=79
- Insufficient relevant  information: n=52
- Duplicates: n=12
- Publication type not of interest (commentaries, 
reviews & other): n=10
- No access to full-text publication: n=1
Included in this Review: Down-titration in RA
Full-text articles: n=10 studies reported in 11 publications
Type of Study Quality Assessment (Risk of Bias)
3 RCTs15, 18, 20 2 excellent,15,20 1 poor18
1 Open-label extension16 ─
4 Observational studies12, 14, 21, 22
(1 was published as efficacy14 and pharmacoeconomic13)
4 good12, 13, 21, 22
2 Pharmacoeconomic studies17, 19 1 good,17 1 fair19
2 Observational studies include pharmacoeconomic data12,22 2 fair12,22
Down-titration in RA
Full-text articles and conference 
abstracts
n=33 studies reported in 42 
publications
Fig. 1  Study disposition
Rheumatol Int 
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Table 2  Dosing and efficacy outcomes in RA down-titration studies, full-text publications
Study citation and type Dose of biologic Efficacy outcome Comments/author conclusions
Smolen et al. [20]
PRESERVE
RCT
OL: ETN50 + MTX qw 
for 36 wk, N = 834 then 
DB: ETN50 + MTX qw, 
n = 202 or ETN25 + MTX 
qw, n = 202 or 
PBO + MTX qw, n = 200
LDA at wk 88:
ETN50 + MTX qw: 166/201 
(82.6%)
ETN25 + MTX qw: 159/201 
(79.1%)
PBO + MTX qw: 84/197 (42.6%)
p < 0.0001, ETN25 or ETN50 vs 
PBO
Author conclusions: ETN standard or 
reduced dose plus MTX is more effec-
tive at maintaining LDA than MTX 
alone
Emery et al. [15]
PRIZE
RCT
OL: ETN50 + MTX qw for 
52 wk, N = 306
then DB for 39 wk: 
ETN25 + MTX qw, n = 63 
or MTX qw, n = 65 or 
PBO, n = 65
Sustained remission at end of DB 
phase:
ETN25 + MTX qw: 40/63 (63%)
MTX qw: 26/65 (40%)
PBO: 15/65 (23%)
p = 0.009, ETN25 + MTX vs 
MTX
p < 0.001, ETN25 + MTX vs PBO
Author conclusions: Following early, 
aggressive treatment, some patients in 
remission or LDA may be considered 
for reduction or withdrawal of the 
biologic; patients should be closely 
monitored
Mariette et al. [18]
SMART
RCT
RTX 1000 mg + MTX on 
days 1 and 15, overall 
population, N = 224
At wk 24: RTX 1000 mg + 
MTX on day 1, PP n = 51
RTX 1000 mg + MTX on 
days 1 and 15, PP n = 49
Over 104 wks, the adjusted 
mean difference in DAS28-
CRP AUC was 51.4 (95% CI 
−131.2 to 234). This was within 
the non-inferiority margin 
of 20% of the reference data 
(mean ± SD = 2218 ± 967; 
20% = 444), indicating non-
inferiority between the two doses
Author conclusions: For patients with a 
EULAR good or moderate response, 
decreasing the subsequent dose of RTX 
is non-inferior to administering the 
standard dose
Keystone et al. [16]
Open-label extension  
of RAPID 1 
400 mg CZP q2w decreased 
to 200 mg q2w, N = 436
Improvements in ACR response 
rates and DAS28-ESR were 
maintained over 192 weeks
–
Borras-Blasco [12]
Observational
N = 24 pts with DAS28 <2.6 
switched from ETN50 qw 
to ETN25 qw
n = 17 pts have continued ETN25 
for a median of 3.5 ± 2.5 year
n = 7 pts discontinued after 
1.8 ± 1.2 year:
 n = 2 pts had adverse event
 n = 5 pts flared: 4 of these 
resumed ETN50 and one 
switched to ADA; all returned to 
clinical remission
Small number of patients in study
Author conclusions: ETN25 may be con-
sidered in patients who have maintained 
remission on ETN50 for ≥1 year and 
have had slow worsening of structural 
changes. However, the appropriate 
patients have not been defined
de la Torre et al. [13] and de la 
Torre et al. [14]
Observational
ADA
Standard dose (S): n = 39
Reduced dose (R): n = 14
ETN:
(S): n = 59
(R): n = 22
INF:
(S): n = 16
(R): n = 2
Remission (DAS28 <2.6)
 ADA (S): 41.0%, ADA (R): 64.3%
 ETN (S): 45.8%, ETN (R): 50.0%
 INF (S): 37.5%, INF (R): 50.0%
LDA (DAS28 2.6–3.2)
 ADA (S): 20.5%, ADA (R): 7.1%
 ETN (S): 10.2%, ETN (R): 27.3%
 INF (S): 6.3%, INF (R): 0%
MDA (DAS28 3.2–5.1)
 ADA (S): 33.3%, ADA (R): 21.4%
 ETN (S): 37.3%, ETN (R): 9.1%
 INF (S): 43.8%, INF (R): 0%
HDA (DAS28 >5.1)
 ADA (S): 5.1%, ADA (R): 7.1%
 ETN (S): 6.8%, ETN (R): 13.6%
 INF (S): 12.5%, INF (R): 50%
Efficacy was measured at 1 visit; patients 
had been receiving an anti-TNF for 
≥12 months; dose taper was allowed 
for patients in remission or LDA 
≥12 months
Author conclusions: For patients who 
have responded clinically, it is reason-
able to attempt a dose decrease; con-
trolled trials are needed to determine 
when the dose can be titrated and which 
patients are appropriate
van den Bemt [21]
Observational
N = 18 pts decreased INF 
from 5 mg/kg to 3 mg/kg 
and were followed for 3 
infusions
16/18 successfully down-titrated
1/18 had persistent flare following 
first low-dose infusion. The flare 
subsided after the INF dose was 
increased
1/18 discontinued due to adverse 
event
Small number of patients in study; three 
infusions may not allow enough time to 
assess progression of RA activity
Author conclusions: Most patients can 
decrease the dose of INF from 5 mg/kg 
to 3 mg/kg; the DAS28 score should be 
monitored
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Results
Literature search
Following the literature search and screening process, 10 
studies published in 11 full-text publications [12–22] quali-
fied for inclusion (Fig. 1). The quality check performed by 
the second reviewer revealed 5 discrepancies out of 374 
publications in level 2 screening, a 1% discrepancy rate 
that fell below the 5% level that would have prompted a re-
evaluation. Qualified publications were identified for five 
biologics: ADA, CZP, ETN, INF, and RTX. No full-text 
publications evaluating down-titration in RA were identi-
fied for TCZ, ABA or GOL.
Efficacy studies
Two RCTs and four observational studies were located for 
TNF inhibitors. Both RCTs evaluated ETN: PRESERVE 
[20] and PRIZE [15]. One RCT for RTX, the SMART study, 
was located [18]. In some publications, down-titration was 
defined as a decrease in the dose, and in others it was defined 
as an extension of the dosing interval. The publications in 
this report that evaluate efficacy are provided in Table 2.
TNF inhibitors
The PRESERVE trial evaluated whether patients could 
maintain LDA following down-titration or withdrawal of 
ETN [20]. Patients had moderate disease activity (DAS28 
>3.2 and ≤5.1) despite methotrexate (MTX) therapy. A 
total of 834 patients received ETN 50 mg (ETN50) weekly 
(qw)  +  MTX qw during an initial 36-week open-label 
period. Patients who achieved sustained LDA (mean DAS28 
≤3.2 from weeks 12 to 36 and DAS28 ≤3.2 at week 36, 
n = 604) were randomized to receive one of three treatments 
(ETN50 + MTX qw, n = 202; ETN25 + MTX qw, n = 202; 
or placebo (PBO) + MTX qw, n = 200) for a double-blind 
period of 52 weeks. The primary endpoint was the propor-
tion of patients maintaining LDA in the ETN50 + MTX and 
PBO + MTX groups at week 88. The proportion of patients 
maintaining LDA at week 88 in the ETN25 + MTX group 
was a conditional primary endpoint.
Significantly more patients in the ETN50 + MTX group 
achieved the primary endpoint than in the PBO + MTX 
group: 166/201 (82.6%) vs 84/197 (42.6%); p < 0.0001 
(Table  2) [20]. The proportion of patients maintaining 
LDA in the ETN25 + MTX group was 159/201 (79.1%); 
p < 0.0001 vs PBO. The efficacy of the ETN50 and ETN25 
doses was not directly compared. Health Assessment 
Questionnaire (HAQ) scores were significantly lower in 
the ETN50 and ETN25 groups compared with PBO, with 
HAQ mean [standard deviation (SD)] scores of 0.5 (0.5) 
for ETN50, 0.6 (0.5) for ETN25, and 0.8 (0.6) for PBO; 
p < 0.0001 for both ETN doses vs PBO.
The number of patients who discontinued during the 
double-blind period due to unsatisfactory responses was 4, 
11, and 43 in the ETN50, ETN25, and PBO groups, respec-
tively. The authors concluded that both standard and reduced 
doses of ETN in combination with MTX are more effective 
in maintaining LDA than MTX alone following discontinu-
ation of ETN.
The PRIZE study enrolled patients with early active 
disease who had not been previously treated with MTX 
or biologic therapy [15]. All patients received open-
label ETN50  +  MTX qw for 52  weeks. Then, patients 
who qualified at weeks 39 and 52 received double-blind 
ETN25 + MTX, or MTX only, or PBO. The qualification 
criteria were DAS28 ≤3.2 at week 39 and DAS28 <2.6 at 
week 52. After 39 weeks of double-blind therapy, patients 
with DAS28 ≤3.2 were withdrawn from treatment. The pri-
mary endpoint was sustained remission (DAS28 <2.6) at 
weeks 24 and 39 of the double-blind phase.
The primary endpoint was achieved by significantly more 
patients in the ETN25 + MTX group [40/63, (63%)] than 
ADA adalimumab, AUC area under the curve, CI confidence interval, CRP C-reactive protein, CZP certolizumab, DAS28 disease activity score 
calculated in 28 joints, DB double-blind, ESR erythrocyte sedimentation rate, ETN etanercept, EULAR European League Against Rheumatism, 
HDA high disease activity, INF infliximab, LDA low disease activity, MDA moderate disease activity, MTX methotrexate, OL open-label, PBO 
placebo, PP per protocol, qw once weekly, q2w every other week, RCT randomized controlled trial, RTX rituximab
Table 2  (continued)
Study citation and type Dose of biologic Efficacy outcome Comments/author conclusions
van der Maas [22]
Observational
N = 51 pts attempted down-
titration of INF. From 
3 mg/kg dose decreased 
by 25% every 8–12 wk for 
1 year until discontinued or 
disease flare
23/51 (45%) successfully down-
titrated:
 3 decreased by 25%
 12 decreased by 50%
 8 decreased by 75%
8/51 (16%) were able to stop INF
20/51 (39%) failed down-titration 
due to flare
Author conclusions: Most patients with 
stable LDA can decrease or discontinue 
INF
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in the MTX only [26/65 (40%); p = 0.009] or PBO group 
[15/65 (23%); p < 0.001] (Table 2) [15]. At the end of the 
double-blind phase, the percentage of patients with a normal 
HAQ score was 78, 72, and 45% for the ETN25 + MTX, 
MTX only, and PBO groups, respectively; p < 0.001 for 
ETN25 + MTX vs PBO. The authors concluded that after 
early, aggressive treatment to achieve remission or LDA, 
a reduction in dose or withdrawal of the biologic may be 
acceptable in some patients, especially those with sustained 
ACR-EULAR Boolean-based remission.
In the open-label extension of the RAPID 1 study, patients 
initially received CZP 400 mg (CZP400) every other week 
(q2w) + MTX [16], then the dosing was changed to CZP200 
q2w. Improvements in DAS28-ESR and ACR response rates 
were maintained over 192 weeks following the dose decrease 
(Table 2).
Four observational studies evaluated dosing down a TNF 
inhibitor in patients with RA (Table 2). A retrospective 
observational study by Borrás-Blasco et al. [12] evaluated 
patients who had achieved and maintained DAS28 <2.6 for 
at least 1 year on ETN50 qw and then were switched to 
ETN25 qw. At study end, 17 of 24 patients were continuing 
ETN25; the median treatment duration was 3.5 ± 2.5 years. 
Seven patients had discontinued ETN25, five of them due 
to disease flare, defined as DAS28 >2.6 (Table 2). Four of 
the patients with flare resumed ETN50, and one switched to 
ADA; all were able to return to clinical remission.
A cross-sectional study by de la Torre et al. [13, 14] 
evaluated patients who had been receiving a TNF inhibitor 
for ≥12 months. Down-titration of the dose was allowed for 
patients who had achieved remission or LDA (DAS28 <2.6 
or <3.2, respectively) for ≥12 months. Efficacy was evalu-
ated at one visit for a total of 195 patients who were receiv-
ing a standard, reduced, or escalated dose of ADA (n = 39, 
14, 3, respectively), ETN (n = 59, 22, 0), or INF (n = 16, 2, 
40), Table 2. Based on a comparison of the response rates 
at standard and reduced doses, the authors concluded that it 
is acceptable to attempt to decrease the dose once patients 
have achieved a clinical response.
A prospective observational study by van den Bemt et al. 
[21] evaluated patients who were receiving INF 5 mg/kg and 
had stable disease activity and DAS28 ≤5.1. The 18 patients 
had been receiving INF 5 mg/kg for a mean (SD) of 19 (14) 
months every 6.1 (1.5) weeks. The dose was decreased to 
3 mg/kg with the dosing interval left unchanged. Patients 
were followed for three infusions; disease flare was defined 
using reversed EULAR response criteria (an increase in 
DAS28 >1.2 or an increase in DAS28 >0.6 and a current 
DAS28 >5.1). A total of 16/18 patients were successfully 
down-titrated (Table 2).
In another prospective observational study, van der Maas 
et al. [22] included patients receiving INF 3 mg/kg with sta-
ble LDA (DAS28 <3.2) and stable therapy for ≥6 months. 
The dose of INF was decreased by 25% every 8–12 weeks 
until it was discontinued or the patient experienced a dis-
ease flare. Flare was defined as an increase in DAS28 ≥1.2 
from baseline on two subsequent visits with ≥2 weeks 
between visits; after the patient reached DAS28 >3.2, then 
flare was defined as an increase in DAS28 ≥0.6. Of the 51 
patients who were included, 23 (45%) were successfully 
down-titrated, 8 (16%) were able to stop INF, and 20 (39%) 
failed down-titration due to flare (Table 2). The difference 
in HRQoL before and after down-titration, as measured by 
the EuroQoL 5-dimensions (EQ5D), was not statistically 
significant.
Rituximab
The SMART study was an open-label non-inferiority study 
in patients with an inadequate response to TNF inhibitors 
[18]. All patients received RTX 1000 mg + MTX for 2 
doses, N = 224. At week 24, patients with a moderate or 
good EULAR response were randomized to receive RTX 
1000 mg for 1 or 2 doses (Table 2). The primary end-
point was DAS28-CRP area under the curve (AUC) over 
104 weeks; the non-inferiority margin was defined as 20% of 
the DAS28-CRP AUC of the reference data (mean = 2218; 
20% = 444). Over 104 weeks, the adjusted mean difference 
in DAS28-CRP AUC was 51.4 (95% CI −131.2–234), indi-
cating non-inferiority between the two doses.
Economic outcomes
Economic data were reported for ADA, ETN, INF, and RTX, 
with most studies reporting a decrease in cost with dosing 
down. Kobelt [17] conducted a cost-effectiveness analysis 
Table 3  Recommended elements to include when designing a dose-titration study
1. A homogeneous patient population with similar levels of disease activity, duration of disease, and prior use of DMARDs and biologics
2. An established definition of disease flare
3. A clear statement on how improvement or relapse is being measured
4. Established definitions of low disease activity, remission, moderate disease activity, partial remission, high disease activity, and/or relapse
5. A statistical comparison of the efficacy of the standard dose and the titrated dose
6. Safety and pharmacoeconomic data
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based on the dosing in the PRESERVE trial. An economic 
model compared the costs of standard and reduced-dose 
ETN to MTX monotherapy in Sweden. In the model, 
patients have LDA at the start. Data were extrapolated out 
10 years using information from the Swedish RA registry. 
The authors estimated the cost per quality-adjusted life-year 
(QALY) gained with ETN25 vs MTX ranged from €14,000 
to €29,000, depending on how long ETN was administered. 
ETN25 had slightly lower costs and similar effectiveness 
compared to ETN50.
In a US retrospective cost analysis, Nair et al. [19] uti-
lized the MarketScan database to compare the medical and 
pharmacy costs of INF resulting from dose decrease, dose 
increase, or no dose change in the first year of treatment. 
The authors found that 29.9 and 24.7% of the 1678 patients 
with commercial insurance maintained and decreased their 
dose, respectively, compared with 17.5 and 43.2% of the 616 
patients with government insurance. Patients with commer-
cial insurance who maintained their dose had significantly 
lower medical costs (per member per year) than those who 
decreased their dose ($21,011 vs $27,697, respectively; 
p = 0.01) and significantly lower pharmacy costs ($2072 vs 
$3229, p = 0.01). For patients with government insurance, 
costs were also lower for maintaining vs decreasing the dose 
(medical: $15,967 vs $18,446; respectively, p = ns; phar-
macy: $2380 vs $3477, p = 0.01). Patients with a decreased 
vs maintenance dose had a significantly higher number of 
inpatient admissions, physician visits, laboratory/diagnostic 
tests, and prescriptions.
In contrast, three observational studies (Table 2) found 
that costs decreased with a lower dose of biologic therapy. 
Van der Maas et al. [22] found that down-titration and dis-
continuation of ETN resulted in a mean decrease in cost 
per patient over 1 year of €3474 (95% CI €2457–€4492). If 
these results were extended to additional years, the authors 
estimated an annual cost savings of €5689 per patient. Bor-
ras-Blasco et al. [12] calculated the direct cost savings from 
using ETN25 rather than ETN50 to be €404,008 during the 
study period of January 2006 to June 2013. Finally, in the 
study by de la Torre et al. [13], the low mean doses of ETN 
(44.9 mg qw) and ADA (37.4 mg q2w) resulted in a savings 
per patient/year of €1223.6 (−10.3%) for ETN and €839.7 
(−6.5%) for ADA.
Discussion
The current treatment strategy in RA is “treat-to-target” 
early in the disease course to prevent permanent joint 
damage [3, 4, 23–25]. Increasingly, clinicians are con-
sidering down-titration, and this consideration is largely 
influenced by cost reduction [8]. This review assessed the 
biologic dose-titration literature in RA to determine whether 
sufficient evidence exists to support the practice of down-
titration. Clinical studies evaluating dosing down of bio-
logics are beginning to be published, and the authors are 
reporting that decreasing the dose of the biologic in patients 
in remission or LDA has some success. However, the study 
results demonstrate that some patients are unable to remain 
in remission and will experience a disease flare.
Sustained remission is the treatment goal in RA to prevent 
permanent joint damage [4]. Although some patients may 
tolerate a reduction in the biologic dose, in other patients, 
tapering biologic therapy after achieving remission may 
increase the risk of disease flare and impact radiographic 
progression. RCT data are limited to date, and additional 
studies are needed to support and guide the practice of dos-
ing down biologic therapy. Finally, although a decreased 
biologic dose may lower drug costs, patients in sustained 
remission will likely have lower healthcare utilization costs 
than patients with active disease. Since we cannot predict 
which patients will tolerate down-titration and which ones 
will experience a disease flare, this practice may not be in 
the best interest of either the healthcare system or the patient 
[13].
This review of the literature identified several limitations 
in the available evidence and discrepancies between the pub-
lications. Few full-text publications were located, and many 
of these studies were observational rather than RCTs. The 
published studies were variable in design and included a 
wide range of baseline disease activity and durations, and 
prior DMARD and biologic use [8, 26]. A standardized 
definition of treatment success or failure was lacking, and 
few studies used established definitions of disease flare. In 
many studies, there was no statistical comparison between 
the standard and decreased dose; the only comparison was 
with PBO or MTX. The quality or risk of bias for most of the 
studies was graded as good to excellent (7 of 11); however, 
3 studies were considered fair and 1 was considered to be of 
poor quality. As a result, it was difficult to draw a conclusion 
as to when and in which patients it may be appropriate to 
attempt down-titration.
Based on the literature review, we have developed sev-
eral recommendations for investigators who are designing a 
dose-titration study (Table 3).
Conclusion
Clinical studies have shown that down-titration of biologic 
therapy in patients with RA who have achieved remission 
or LDA is successful in many patients. Additionally, most 
studies that conducted a cost analysis determined that costs 
decrease when the dose of the biologic decreases. However, 
the study results also demonstrated that following down-
titration, some patients are unable to maintain remission or 
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LDA and experience a disease flare. Since their RA is no 
longer under control, these patients may be at risk for joint 
damage. Additional well-designed, high-quality RCTs that 
use standardized definitions of remission and disease flare 
are needed to provide guidance to clinicians on whether 
dosing down biologic therapy is appropriate for particular 
patients.
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